Another retrospective case series showed a correlation between different cutaneous and extra-cutaneous adverse events including vitiligo, erythema nodosum, uveitis and keratitis sicca and the treatment outcome upon BRAF inhibitors either administered alone or in combination with MEK inhibitors (12). This evidence concerns the gene MAP2K7 and vitiligo.